Clinical Indication

Myeloproliferative disorders, sickle cell anaemia


Full SCA

Date of classification

January 2010


Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.